Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
OncoC4, Inc.
Rutgers, The State University of New Jersey
Massachusetts General Hospital
Eli Lilly and Company
Merck Sharp & Dohme LLC
University of Pittsburgh
Ascendis Pharma A/S
Qurient Co., Ltd.
University of Pittsburgh
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
University of Oklahoma
ImmunityBio, Inc.
Novartis
Dana-Farber Cancer Institute
BicycleTx Limited
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
University Health Network, Toronto
University of Washington
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Toray Industries, Inc
City of Hope Medical Center
Merck Sharp & Dohme LLC
OncoC4, Inc.
North Eastern German Society of Gynaecological Oncology
Compugen Ltd
Dana-Farber Cancer Institute
University Health Network, Toronto
Carisma Therapeutics Inc
NextCure, Inc.
ARCAGY/ GINECO GROUP
Merck Sharp & Dohme LLC
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
NETRIS Pharma
NGM Biopharmaceuticals, Inc
ENB Therapeutics, Inc
Adlai Nortye Biopharma Co., Ltd.
Jonsson Comprehensive Cancer Center
ImmunoVaccine Technologies, Inc. (IMV Inc.)